Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdf
   Google Scholar
• National Institute for Healthcare and Excellence (NICE) Guidelines. Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management 2010. Available from: http://www.nice.org.uk/guidance/cg101
   Google Scholar
• Rosenberg SR, Kalhan R. An integrated approach to the medical treatment of chronic obstructive pulmonary disease. Med ClinNorth Am 2012; 96(4):811–826.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bailey W, Crater G, Emmett A, O'Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J 2011; 20(1):46–53.
   PubMedGoogle Scholar
• Diette GB, Orr P, McCormack MC, Gandy W, Hamar B. Is pharmacologic care of chronic obstructive pulmonary disease consistent with the guidelines? Popul Health Manage 2010; 13(1):21–26.
   PubMed Web of Science ®Google Scholar
• Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin 2011; 27(7):1425–1429.
   PubMed Web of Science ®Google Scholar
• Salinas GD, Williamson JC, Kalhan R, Thomashow B, Scheckermann JL, Walsh J, et al. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis 2011; 6:171–179.
   PubMed Web of Science ®Google Scholar
• Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi JD. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly 2010; 140:1–8. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Perez X, Wisnivesky JP, Lurslurchachai L, Kleinman LC, Kronish IM. Barriers to adherence to COPD guidelines among primary care providers. Respir Med 2012; 106(3):374–381.
   PubMed Web of Science ®Google Scholar
• White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids–implications for safety and costs: cross-sectional observational study. PLoS One 2013; 8(10):e75221. doi: 10.1371/journal.pone.0075221.eCollection2013.
   PubMed Web of Science ®Google Scholar
• Clinical Practice Research Datalink (CPRD). Accessed October 4, 2012. Available from: http://www.cprd.com/home/.
   Google Scholar
• Rothnie KJ, Müllerová H, Hurst JR, Smeeth L, Davis K, Thomas SL, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS ONE 2016; 11(3):e0151357.
   PubMed Web of Science ®Google Scholar
• Punekar YS, Landis S, Wurst K, Le H. Characteristics, disease burden and costs of COPD patients up to two years after initiation of long-acting bronchodilators in UK primary care. Respir Res 2015; 16:141. doi: 10.1186/s12931-015-0295-2.
   PubMed Web of Science ®Google Scholar
• Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PloS One 2014; 9(9):e105296.
   PubMed Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keininger DL, Stewart R, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis 2015; 10:2207–2217.
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J 2015; 45(4):969–979.
   PubMed Web of Science ®Google Scholar
• Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med 2014; 2(6):472–486.
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi MR KT, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med 2014; 108(12):1752–1760.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42(6):1484–1494.
   PubMed Web of Science ®Google Scholar
• Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis 2014; 9:889–904.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Malerba M, Santini G, Miravitlles M. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping Drug Discovery Today 2014; 19(12):1928–1935.
   Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem 2015; 58:4131–4164.
   PubMed Web of Science ®Google Scholar
• Wurst KE, St Laurent S, Mullerova H, Davis KJ. Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study. Int J Chron Obstruct Pulmon Dis 2014; 9:1021–1031.
   PubMed Web of Science ®Google Scholar
• Osman LM, Hyland ME. Patient needs and medication styles in COPD. Eur Respir Rev 2005; 14(96):89–92.
   Google Scholar